BullFrog AI Holdings (BFRG) Liabilities and Shareholders Equity (2021 - 2026)
BullFrog AI Holdings' (BFRG) quarterly Liabilities and Shareholders Equity came in at $7.7 million in Q2 2026, up 168.15% on a YoY basis from $2.9 million in Q2 2025, and up 173.96% quarter-over-quarter from $2.8 million in Q4 2025.
Analysis
BullFrog AI Holdings (BFRG) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
BullFrog AI Holdings (BFRG) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $7.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 168.15% year-over-year to $7.7 million; the trailing twelve-month figure through Jun 2026 stood at $16.1 million (down 6.05% YoY), and the FY2025 full-year result was $2.8 million, down 49.42% from the prior year.
- Liabilities and Shareholders Equity advanced to $7.7 million in Q2 2026 per BFRG's latest filing, from $2.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $7.7 million in Q2 2026 and bottomed at $80369.0 in Q4 2022.
- Historically, Liabilities and Shareholders Equity has averaged $4.5 million across 5 years, with a median of $4.4 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity surged 3354.8% in 2023, then plunged 52.78% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $80369.0 in 2022, then soared by 3354.8% to $2.8 million in 2023, then soared by 99.95% to $5.6 million in 2024, then plunged by 49.42% to $2.8 million in 2025, then soared by 173.96% to $7.7 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $7.7 million, $2.8 million, and $2.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 2.10 Bn |
| 10 | BullFrog AI Holdings | 9.27 Mn | 2.35 Mn | 106,899.00 | 7.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.69 Mn |
| Dec 31, 2025 | 2.81 Mn |
| Sep 30, 2025 | 2.70 Mn |
| Jun 30, 2025 | 2.87 Mn |
| Mar 31, 2025 | 4.09 Mn |
| Dec 31, 2024 | 5.55 Mn |
| Sep 30, 2024 | 4.60 Mn |
| Jun 30, 2024 | 6.08 Mn |
| Mar 31, 2024 | 7.65 Mn |
| Dec 31, 2023 | 2.78 Mn |
| Sep 30, 2023 | 4.21 Mn |
| Jun 30, 2023 | 6.04 Mn |
| Mar 31, 2023 | 6.23 Mn |
| Dec 31, 2022 | 80,369.00 |
| Dec 31, 2021 | 10,014.00 |